Last reviewed · How we verify

TAR-210 — Competitive Intelligence Brief

TAR-210 (TAR-210) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific antibody. Area: Oncology.

phase 3 Bispecific antibody PD-1 and LAG-3 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

TAR-210 (TAR-210) — Janssen Research & Development, LLC. TAR-210 is a bispecific antibody targeting the PD-1 and LAG-3 immune checkpoint proteins.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
TAR-210 TARGET TAR-210 Janssen Research & Development, LLC phase 3 Bispecific antibody PD-1 and LAG-3
Nivolumab + Relatlimab Nivolumab + Relatlimab H. Lee Moffitt Cancer Center and Research Institute marketed Dual checkpoint inhibitor (PD-1 and LAG-3 inhibitor combination) PD-1 and LAG-3
AK112, Gemcitabine, Cisplatin AK112, Gemcitabine, Cisplatin Akeso phase 3 Bispecific antibody (PD-1/LAG-3 inhibitor) combined with chemotherapy PD-1 and LAG-3
AK112, Carboplatin, Paxlitaxel AK112, Carboplatin, Paxlitaxel Akeso phase 3 Bispecific antibody (PD-1/LAG-3 inhibitor) + chemotherapy combination PD-1 and LAG-3
Nivolumab-relatlimab FDC Nivolumab-relatlimab FDC Bristol-Myers Squibb phase 3 Dual checkpoint inhibitor (PD-1/LAG-3) PD-1 and LAG-3
BAT2206 BAT2206 Bio-Thera Solutions phase 3 Bispecific antibody; dual checkpoint inhibitor Likely PD-1 and LAG-3 (or similar dual checkpoint targets)
Elrexfio elranatamab Pfizer marketed Bispecific antibody BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells 2023-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific antibody class)

  1. Shanghai Miracogen Inc. · 3 drugs in this class
  2. Atom Therapeutics Co., Ltd · 2 drugs in this class
  3. Pfizer · 2 drugs in this class
  4. Allergan · 1 drug in this class
  5. AstraZeneca · 1 drug in this class
  6. BioNTech SE · 1 drug in this class
  7. DualityBio Inc. · 1 drug in this class
  8. Coherus Oncology, Inc. · 1 drug in this class
  9. Genmab · 1 drug in this class
  10. Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TAR-210 — Competitive Intelligence Brief. https://druglandscape.com/ci/tar-210. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: